Effects of Ubiquinol and/or D-ribose in Patients With Heart Failure With Preserved Ejection Fraction

Pierce, Janet D.; Shen, Qiuhua; Mahoney, Diane E.; Rahman, Faith; Krueger, Kathryn J; Díaz, Francisco Javier Rodríguez; Clark, Lauren; Smith, Carol E.; Vacek, James L.; Hiebert, John M.

doi:10.1016/j.amjcard.2022.04.031

Cited by 12 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result, it is utilized as a therapeutic agent to improve cardiac function in patients with HF. Research shows that Supplemental d-ribose reduces the symptoms of HFpEF and increases EF ( Pierce et al, 2022 ). Our study indicates that SFI can increase D ribose and Sedoheptulose levels.…”

Section: Discussionmentioning

confidence: 99%

Shenfu injection improves isoproterenol-induced heart failure in rats by modulating co-metabolism and regulating the trimethylamine-N-oxide - inflammation axis

Li,

Ye,

Zhao

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Heart failure (HF) is a chronic condition that progressively worsens and continues to be a major financial burden and public health concern. The “gut-heart” axis provides an innovative perspective and therapeutic strategy for preventing and treating heart failure. Shenfu injection (SFI) is a Traditional Chinese Medicine-based treatment demonstrating potential as a therapeutic strategy for heart failure. However, the precise therapeutic mechanisms of SFI in heart failure are not completely characterized. In this study, HF models were established utilizing subcutaneous multipoint injection of isoproterenol (ISO) at a dosage of 5 mg kg−1·d−1 for 7 days. Serum levels of inflammatory biomarkers were quantified using protein microarrays. Rat feces were analyzed using untargeted metabolomics research and 16S rRNA sequencing. The link between gut microbiota and metabolites was examined using a MetOrigin and Spearman correlation analysis. Our results show that Shenfu injection effectively enhances cardiac function in rats with ISO-induced heart failure by potentially modulating pro-/anti-inflammatory imbalance and reducing serum and urine Trimethylamine-N-oxide (TMAO) levels. Moreover, SFI significantly increases the abundance of Bacteroidota at the phylum level, thereby improving disrupted gut microbiota composition. Additionally, SFI supplementation enriches specific genera known for their capacity to produce short-chain fatty acids. SFI was found to be associated with three key metabolic pathways, as revealed by fecal metabonomics analysis, including the pentose phosphate pathway, pyrimidine metabolism, and purine metabolism. Metabolite tracing analysis revealed that Taurine and hypotaurine metabolism was found to be specific to the microbial community. The biosynthesis of Pyrimidine metabolism, Purine metabolism, beta-alanine metabolism, Naphthalene degradation, Pantothenate, and CoA biosynthesis were identified as co-metabolic pathways between microbes and host. The Spearman correlation analysis was also significantly correlated to differentially expressed metabolites regulated by SFI and the gut microbiota. These results suggest that SFI improves ISO-induced heart failure by modulating co-metabolism and regulating the TMAO-inflammation axis.

show abstract

Section: Discussionmentioning

confidence: 99%

Shenfu injection improves isoproterenol-induced heart failure in rats by modulating co-metabolism and regulating the trimethylamine-N-oxide - inflammation axis

Li,

Ye,

Zhao

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Supplementation with these two substances may enhance the quality of life for patients with HFpEF. A 12-week treatment with 600 mg of ubiquinol or 15 g of D-ribose per day reduced HF symptoms, decreased levels of B-type natriuretic peptide (BNP) and lactate, and increased EF and ATP production [ 31 ].…”

Section: Pharmacological and Non-pharmacological Treatments Of Hfpefmentioning

confidence: 99%

Pharmacological and Non-Pharmacological Advancements in Heart Failure Treatment

Wang,

Fu,

Wang

et al. 2024

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Heart failure (HF) is a complex, life-threatening condition characterized by high mortality, morbidity, and poor quality of life. Despite studies of epidemiology, pathogenesis, and therapies, the rate of HF hospitalization is still increasing due to the growing and aging population and an increase in obesity in relatively younger individuals. It remains a predominant issue in the public health and the global economic burden. Current research has focused on how HF affects the entire range of left ventricular ejection fraction (LVEF), especially the three HF subgroups. This review provides a latest overview of pharmacological and non-pharmacological strategies of these three subgroups (HF with preserved ejection fraction, HF with reduced ejection fraction, and HF with mildly reduced ejection fraction). We summarize conventional therapies, investigate novel strategies, and explore the new technologies such as aortic thoracic stimulation and interatrial shunting devices.

show abstract

Lifestyle interventions in cardiometabolic HFpEF: dietary and exercise modalities

Vacca,

Wang,

Nambiar

et al. 2024

Heart Fail Rev

View full text Add to dashboard Cite

Heart failure with preserved ejection fraction (HFpEF) is rapidly growing as the most common form of heart failure. Among HFpEF phenotypes, the cardiometabolic/obese HFpEF — HFpEF driven by cardiometabolic alterations — emerges as one of the most prevalent forms of this syndrome and the one on which recent therapeutic success have been made. Indeed, pharmacological approaches with sodium-glucose cotransporter type 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have proved to be effective due to metabolic protective effects. Similarly, lifestyle changes, including diet and exercise are crucial in HFpEF management. Increasing evidence supports the important role of diet and physical activity in the pathogenesis, prognosis, and potential reversal of HFpEF. Metabolic derangements and systemic inflammation are key features of HFpEF and represent the main targets of lifestyle interventions. However, the underlying mechanisms of the beneficial effects of these interventions in HFpEF are incompletely understood. Hence, there is an unmet need of tailored lifestyle intervention modalities for patients with HFpEF. Here we present the current available evidence on lifestyle interventions in HFpEF management and therapeutics, discussing their modalities and potential mechanisms.

show abstract

Effects of Ubiquinol and/or D-ribose in Patients With Heart Failure With Preserved Ejection Fraction

Cited by 12 publications

References 29 publications

Shenfu injection improves isoproterenol-induced heart failure in rats by modulating co-metabolism and regulating the trimethylamine-N-oxide - inflammation axis

Shenfu injection improves isoproterenol-induced heart failure in rats by modulating co-metabolism and regulating the trimethylamine-N-oxide - inflammation axis

Pharmacological and Non-Pharmacological Advancements in Heart Failure Treatment

Lifestyle interventions in cardiometabolic HFpEF: dietary and exercise modalities

Contact Info

Product

Resources

About